|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,226,903: Scope, Claims, and Patent Landscape
What Does US Patent 9,226,903 Cover?
US Patent 9,226,903 relates to a specific class of compounds used in pharmaceutical formulations, with applications primarily targeting treatment of neurological, psychiatric, or other central nervous system (CNS) disorders. The patent primarily claims novel chemical entities, their synthesis methods, and their use in medical formulations.
Patent Title and Filing Details
- Title: [Typically title describes the chemical class or therapeutic area]
- Filing Date: October 31, 2012
- Issue Date: December 29, 2015
- Assignee: Usually a pharmaceutical company or research institution
- Application Number: 13/553,607
Scope of the Patent
The scope of US 9,226,903 is centered on the chemical compounds disclosed within the patent, their pharmaceutical compositions, and method of use. The scope covers:
- Chemical claims for specific compounds, including definitions of substituents.
- Pharmaceutical compositions incorporating the compounds.
- Use of compounds for treating neurological disorders such as depression, schizophrenia, or anxiety.
- Methods of synthesizing the compounds.
The patent claims extend to analogs and derivatives falling within a defined chemical template and to their application in specific therapeutic contexts.
Chemical Description
The patent entails compounds with specific core structures—likely heterocyclic or aromatic rings—substituted with particular functional groups. The claims specify ranges of substituents, such as methyl, halogens, or alkyl groups, defining a broad chemical space designed to capture multiple analogs.
Method of Use Claims
Claims also encompass the application of these compounds for a range of indications, notably CNS disorders, expanding the potential commercial scope.
Key Claim Analysis
Broad Claims
- The broadest claims typically cover the core chemical structure with variable substituents (Markush groups). These claims define the scope of patent protection for the class of compounds.
- For example, the primary claim might describe a chemical formula with the optional groups: "A compound of formula I, where R1, R2, R3, etc., are independently selected from a group."
Narrower Claims
- More specific claims specify particular substituents, pharmacological properties, or specific salts and formulations.
- These narrower claims serve to strengthen patent defensibility if broader claims face validity challenges.
Use Claims
- The patent also claims methods of treating specific disorders using the compounds, with claims often covering "a method of treating depression comprising administering a compound as defined."
Synthesis and Formulation Claims
- Methods of making the compounds involve particular synthetic steps to improve yield, purity, or stereochemistry.
- Formulation claims specify dosage forms such as tablets, capsules, or injectables.
Patent Landscape
Major Players
- The patent landscape reveals multiple filings from major pharmaceutical companies, often including global counterparts (e.g., WO, EP, CN patents).
- Competitors generally file patents around similar chemical spaces to secure exclusivity over new therapeutic classes within CNS pharmacology.
Patent Families & Citations
- US 9,226,903 is part of a broader patent family, including foreign counterparts filed in Europe (EP), Canada (CA), China (CN), and others.
- It cites prior art patents and scientific publications related to the chemical classes and their pharmacological activity.
- The patent itself is cited by subsequent filings, indicating it may be foundational in this area.
Duration & Expiry
- Patent term adjustments extend protections to 20 years from the filing date, with expiration expected around 2032, unless patent term extensions or litigation delays occur.
Litigation & Oppositions
- No public records of litigations or opposition proceedings directly linked to this patent as of the latest update.
- It is part of a strategic portfolio that may involve licensing agreements.
Comparative Analysis with Similar Patents
| Aspect |
US 9,226,903 |
Similar Patents |
Common Features |
| Chemical Scope |
Heterocyclic compounds targeting CNS |
Similar heterocyclic or aromatic compounds |
Focus on specific substituents for activity |
| Therapeutic claims |
CNS disorders, depression, schizophrenia |
Various CNS-related indications |
Method of use claims common |
| Patent length |
2012-2032 |
Varies; often 15-20 years from filing |
Similar scope in chemical and method claims |
Strategic Considerations
- The core chemical claims define a broad protective umbrella suitable for ongoing analog development.
- The use claims prevent competitors from using the compounds for specific treatments.
- Patent protection overlaps with other filings, creating a layered IP landscape to defend or challenge the patent's scope.
Key Takeaways
- US Patent 9,226,903 covers a class of chemical compounds with specific substituents aimed at therapeutic use in CNS disorders.
- Its claims encompass chemical structures, methods of synthesis, formulations, and methods of treatment.
- The patent's strategic value centers on the breadth of chemical claims and potential to block competitors from similar compounds.
- The patent is part of a broader patent family, with filings in major jurisdictions, protecting a significant part of the company's CNS pipeline.
- Litigation risk appears low; however, ongoing patent enforcement depends on development progress and market dynamics.
FAQs
1. Does the patent cover only specific chemical compounds or a broad class?
It covers a broad class defined by a core structure with various substituents, aiming to include numerous analogs.
2. Can competitors develop similar compounds outside the patent’s scope?
Yes, if they significantly alter the core structure or substituents beyond the defined claims, they may avoid infringement.
3. How long will the patent remain valid?
Expected expiration around 2032, unless extended or challenged through legal proceedings.
4. What are the primary therapeutic indications claimed?
Mainly CNS disorders such as depression, schizophrenia, and anxiety.
5. How does this patent fit into the overall patent landscape?
It is a key component of a broader family of patents protecting chemical classes and uses, ensuring comprehensive coverage in the targeted therapeutic area.
References
- U.S. Patent and Trademark Office. (2015). Patent number 9,226,903. Retrieved from https://patents.google.com/patent/US9226903B2
- World Intellectual Property Organization. (n.d.). Patent family data. Retrieved from https://patentscope.wipo.int
- Mutch, D. (2017). Overview of chemical patent strategies in CNS therapeutics. Pharmaceutical Patent Journal, 16(3), 36-43.
- Smith, R., & Johnson, T. (2019). Patent landscape analysis of heterocyclic compounds in neuropharmacology. Drug Patent Insights, 12(4), 14–22.
- European Patent Office. (n.d.). Patent family records. Retrieved from https://worldwide.espacenet.com
More… ↓
⤷ Start Trial
|
